Asia Pacific Red Biotechnology Market Size & Outlook
Asia Pacific red biotechnology market, 2018-2030 (US$M)
Related Markets
Asia Pacific red biotechnology market highlights
- The Asia Pacific red biotechnology market generated a revenue of USD 110,463.0 million in 2023.
- The market is expected to grow at a CAGR of 16% from 2024 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2023.
- Gene Therapy Products is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 110,463.0 million |
| Market revenue in 2030 | USD 311,982.2 million |
| Growth rate | 16% (CAGR from 2023 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Gene Therapy Products |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Proteins, Vaccines, Cell-Based Immunotherapy Products, Gene Therapy Products, Cell Therapy Products, Tissue-Engineered Products, Stem Cells, Cell Culture, Viral Vector, Enzymes, Kits and Reagents, Animal Models, Molecular Diagnostics |
| Key market players worldwide | Merck KGaA, Roche Holding AG ADR, Pfizer Inc, Regeneron Pharmaceuticals Inc, AstraZeneca PLC, Gilead Sciences Inc, Biogen Inc, Amgen Inc, Bristol-Myers Squibb Co, Takeda Pharmaceutical Co Ltd |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 22.4% of the global red biotechnology market in 2023.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 311,982.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Red Biotechnology Market Scope
Red Biotechnology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific red biotechnology market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to red biotechnology market will help companies and investors design strategic landscapes.
Monoclonal antibodies was the largest segment with a revenue share of 49.76% in 2023. Horizon Databook has segmented the Asia Pacific red biotechnology market based on monoclonal antibodies, polyclonal antibodies, recombinant proteins, vaccines, cell-based immunotherapy products, gene therapy products, cell therapy products, tissue-engineered products, stem cells, cell culture, viral vector, enzymes, kits and reagents, animal models, molecular diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Asia Pacific red biotechnology market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific red biotechnology market databook
-
Our clientele includes a mix of red biotechnology market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific red biotechnology market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific red biotechnology market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific red biotechnology market size, by country, 2018-2030 (US$M)
Asia Pacific Red Biotechnology Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
